Celgene announced on Tuesday that it will acquire biopharmaceutical company
Receptos for $232 per share in cash, for a total of about $7.2 billion net cash acquired.
NEWS after hours that Another huge buyout in the biotech sector... seems today these companies are willing to pay top dollar for their competitors and are grossly, grossly, grossly over paying to buy each and every one of them out.....this sector is in a bubble....
$7.3 BILLION TO BUY them out, last year at this time the company had a market value of just about a billion dollars.....in one year their market cap grew from $1 Billion to over $7 billion...I have no idea how this company can have a valuation of $7 BILLION based on their quarterly earnings reports especially the last one
From March 2015
The San Diego, California-based company posted a quarterly loss of $38.2 million, or $1.32 per share, versus a year-ago loss of $15.2 million, or $0.86 per share. The latest quarter net loss included $3.4 million in stock-based compensation expense, versus $1.3 million in the year-ago quarter. Analysts were expecting the company to post a loss of $1.19 per share.
Its total revenue came in at $0 in the quarter, versus $773,000 in the year-ago period. Total revenue for 2014 climbed to $5.9 million, from $4.6 million in 2013.
Total operating expenses rose to $37.2 million from $15.9 million.
Research and development expenses increased to $32.0 million from $12.6 million in the year-ago quarter, while general and administrative expenses rose to $5.2 million from $3.2 million.
Read more:
http://www.benzinga.com/news/earnin...te-receptos-posts-wider-q4-loss#ixzz3fu956Kj3
Celgene announced on Tuesday that it will acquire biopharmaceutical company
Receptos for $232 per share in cash, for a total of about $7.2 billion net cash acquired.